Study of Tofacitinib in Refractory Dermatomyositis

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT03002649
• Date of registration: 20/12/2016
• Prospective Registration: Yes
• Primary sponsor: Johns Hopkins University
• Public title: Study of Tofacitinib in Refractory Dermatomyositis STIR
• Scientific title: Study of Tofacitinib in Refractory Dermatomyositis (STIR): Proof of Concept, Open-Label Study of 10 Patients
• Date of first enrolment: January 2017
• Target sample size: 10
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT03002649
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 1

Countries of recruitment

United States

Contacts

• Name: Julie Paik, MD
• Affiliation: Johns Hopkins University

Key inclusion & exclusion criteria

Inclusion Criteria:

Study subjects must meet the following criteria:

- Definite or probable dermatomyositis by Bohan and Peter Criteria at least 6 months
before screening

- Active skin disease as defined by a CDASI score of at least 5

- Skin biopsy proven disease

- Although not mandatory, patients with muscle weakness are eligible for enrollment.
Those with active muscle disease must have a Manual Muscle Testing (MMT-8) score < 142
out of 150

- Age > 18

- Refractory myositis is defined by active disease despite a 12 week trial of steroids
and with failure of response to at least prednisone and 1 other first line
immunosuppressive agents (e.g. methotrexate, mycophenolate mofetil, or azathioprine)
OR have demonstrated significant toxicity or intolerance to such therapies

- Maximum prednisone dose allowed will be 20mg/daily at time of entry to study provided
that the dose has been stable for at least 2 weeks prior to baseline. Patients should
not have received a daily therapy of more than 80mg of prednisone equivalent within 8
weeks prior to study entry

- Negative cancer screening conducted in the 6 months prior to screening visit

- Washout of immunosuppressive agents will be as follows:

1. Azathioprine, mycophenolate, tacrolimus: 12-16 weeks prior to first dose of study
drug;

2. Rituximab: 12 months;

3. Intravenous Immunoglobulin (IVIg): 3 months;

4. Cyclophosphamide: 1 year;

5. Methotrexate: 12-16 weeks.

- Women of child-bearing potential must have negative pregnancy test and be willing to
undergo urine pregnancy testing at every on-site visit for the duration of the study

- Must provide informed consent

- Must be willing and able to comply with the requirements of the protocol

Exclusion Criteria:

The presence of any of the following excludes subject participation in the study:

- Use of other investigational drugs at the time of enrollment

- History of hypersensitivity to any of the study drugs or drugs of similar chemical
classes

- DM patients having overlap myositis attributable to other causes such as scleroderma,
arthritis, statin myopathy, steroid induced myopathy and/or significant organ damage
e.g. lupus nephritis, central nervous system are present

- Late stage DM whose muscle weakness, according to the Investigator, could be
attributable to muscle damage rather than myositis disease activity

- Patients with other types of myositis or myopathies: polymyositis, paraneoplastic
myositis, inclusion body myositis, metabolic or drug induced myopathy, dystrophies

- Inclusion body myositis, Juvenile dermatomyositis or polymyositis, or myositis in
overlap with other rheumatic diseases such as lupus, scleroderma, Sjogren's, or
vasculitis

- Patients with advanced clinically symptomatic interstitial lung disease

- Pregnancy or breast-feeding patients

- History of bowel rupture or inflammatory bowel diseases

- History of tuberculosis or mycobacterial infections

- Recent infection in the past 4 weeks before entry of study

- History of any malignancy of any organ system (other than localized basal cell
carcinoma of the skin), treated or untreated, within the past 5 years, regardless of
whether there is evidence of local recurrence or metastases

- Active systemic bacterial, viral or fungal infections, or diagnosis of AIDS, Hepatitis
B, Hepatitis C infection

- Diverticulitis or ulcers in stomach or intestines

- Evidence of any other acute or chronic infectious diseases

- Have received any live or live attenuated vaccines (including varicella or measles)
within 2 months prior to study enrollment

- Patients with any of the following hepatic conditions prior to study: (a) history of
chronic liver or biliary disease, (b) total conjugated bilirubin greater than 1.5
times upper limits of normal (ULN) range, unless in the context of Gilbert's syndrome,
(c) alkaline phosphatase greater than 1.5 times the ULN range, (d) aspartate
transaminase (AST), alanine transaminase (ALT) greater than 3 times the ULN if the
elevation of AST or ALT, according to the investigator, is attributable to liver
disease. Patients with elevated AST/ALT due to myositis disease activity are eligible,
(e) Gamma-glutamyltransferase (GGT) greater than 3 times the ULN range

- Current or recent history of uncontrolled renal, hepatic, hematological,
gastrointestinal, metabolic, endocrine, pulmonary, cardiac, or neurological disease

- Blood dyscrasias within 3 months prior to the first dose of study medication,
including confirmed:

1. Hemoglobin <9 g/dL or Hematocrit <30%;

2. White blood cell count <3.0 x 109/L;

3. Absolute neutrophil count <1.2 x 109/L;

4. Platelet count <100 x 109/L.

- Estimated glomerular filtration rate (GFR) <40 ml/min based on Cockcroft-Gault
calculation



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Dermatomyositis

Intervention(s)

Drug: Tofacitinib

Primary Outcome(s)

Number of participants who achieve International Myositis Assessment and Clinical Studies (IMACS) Definition of Improvement (DOI) [Time Frame: Up to 12 weeks]

Secondary Outcome(s)

Safety and tolerability of tofacitinib as assessed by frequency of adverse events reported and observed [Time Frame: Up to 16 weeks]

Safety and tolerability of tofacitinib as assessed by incidence of adverse events reported and observed [Time Frame: Up to 16 weeks]

Change from baseline in CDASI activity score [Time Frame: Up to 16 weeks]

Secondary ID(s)

IRB00084227

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Pfizer